The potential value of genomic surveillance of nosocomial pathogens for outbreak detection and investigation is high but will result in an up-front cost. This early model indicates that proactive genomic surveillance of MRSA is likely to be cost effective. 
INTRODUCTION
Hospital outbreak detection is founded on principles used by John Snow during his investigation of a cholera epidemic [1] . Routine surveillance identifies patients who carry or are infected with specific pathogens, which is reviewed in relation to patient movement data and other information that could link cases. The identification of two or more patients positive for the same pathogenic species who are also linked in time and place triggers an assessment of the probability of an outbreak. In the case of bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), this assessment may incorporate routine data generated by the microbiology laboratory on antibiotic resistance. The pattern of resistance to the range of antibiotics tested in the laboratory is used as a surrogate for bacterial relatedness, although this lacks sensitivity and specificity. If the initial investigation concludes that an outbreak is possible or likely, formal typing methods may be used to define bacterial relatedness. Available typing methods lack sensitivity because of their low power to discriminate between isolates that reside in the same clone and can erroneously link isolates that are not recently related [2] [3] [4] . Ultimately, the confirmation of an outbreak is based on a combination of imperfect evidence and the intuition of experienced infection control staff.
Whole Genome Sequencing (WGS) represents a major advance in the control of multidrugresistant organisms (or other organisms) that spread between patients, units and facilities.
When combined with patient movement data, this provides a more accurate determination of transmission events and outbreak status than standard infection control methods alone [2] [3] [4] [5] [6] [7] .
One option for the uptake of bacterial sequencing into clinical practice is to simply swap the typing methods used during an outbreak investigation, but there would be several advantages of a process redesign in which sequencing was used proactively [8] . This would begin with the routine sequencing of specific bacterial species of interest and quantitation of genetic relatedness between isolates of the same species. Following sequencing, the decision to investigate (or not) would be based on a desk-based analysis of the degree of relatedness combined with information on patient movement. This model would support efficient, highly targeted infection control interventions provided that data can be generated rapidly and in a format that does not require specialist informatics knowledge. Early evidence for the potential benefits of this 'Sequence First' approach comes from a study of genomic surveillance of MRSA isolated in a large clinical microbiology laboratory in the East of England over 12 months [6] . This led to the identification of hundreds of transmission clusters which were not detected by standard infection control. This highlights a missed opportunity for greater control through early outbreak detection followed by action to minimise on-going transmission.
The potential value of genomic surveillance of nosocomial pathogens is compelling but will result in an up-front cost. One rationale to support this cost is to align outbreak detection with other types of activity that relate to safety culture, which are fully justified on the basis that they save lives through prevention, rapid detection and effective action. However, evidence of cost effectiveness is often demanded of changes in healthcare practice.
METHODS

Model Overview
The aim of the model was to estimate the cost-effectiveness of whole genome sequencing of MRSA combined with standard infection control practice versus standard practice alone. A decision tree framework (Figure 1 ) was used to estimate the reduction in total number of MRSA acquisitions (including any subsequent infection), and hence the cost effectiveness of whole genome sequencing over one year based on an annual cohort of newly admitted The model was built from the National Health Service (NHS) and personal social services perspective, which is consistent with The National Institute for Health and Care Excellence (NICE) reference case [9] . As the model only estimated the cost effectiveness of whole genome sequencing within one annual cohort of hospitalised patients, the discounting of costs and benefits was not necessary. Per-patient Quality Adjusted Life Years (QALYs) were generated and the primary outcome of the model was the incremental cost per QALY gained.
Data sources and model parameters
Classification of Patients
Data generated during a 12-month prospective observational cohort study between April 2012 and April 2013 were used to inform patient classification [6] . In brief, the Clinical 
Effectiveness Inputs
The effectiveness of whole genome sequencing was based on the relative reduction in total number of MRSA acquisitions that occurred in a cohort of hospitalised patients in the year following their index admissions. The number of annual MRSA acquisitions expected within current practice (with data from the 12 month observational cohort study used as a proxy), was multiplied by the relative reduction to estimate the reduction in number of MRSA acquisitions following whole genome sequencing implementation. Due to a lack of published data to date, the likely size of this relative reduction of MRSA acquisition is hypothetical (Table I ). The probability of an MRSA negative patient acquiring MRSA whilst in hospital was assumed to be 0.5%, in lieu of forthcoming data from an on-going clinical evaluation at Cambridge University Hospitals. To explore the implications of these assumptions on the cost effectiveness of whole genome screening, both inputs were varied in the sensitivity analyses.
MRSA-related mortality
Within the early model, we assumed that 4.6% of all symptomatic infected MRSA inpatients (involving any site or organ) die of MRSA-related causes before hospital discharge (Table I) .
This value came from a retrospective analysis of US National Inpatient Sample data from 2010 to 2014, where 358,140 MRSA-related hospitalisations were recorded [10] . Consistent with the previous literature [11] , we assumed that colonised patients with no infection faced no MRSA associated mortality risk.
Costs
We identified only one economic evaluation from a targeted literature search of MRSA surveillance and screening strategies in the United Kingdom, which reported the cost of an MRSA infected patient when admitted to an intensive care unit [12] . However, they did not report the cost of colonisation and we used a Canadian paper as the source for this parameter [11] . The paper reported the cost per case of positive asymptomatic MRSA colonisation in Canadian Dollars, which was converted into British Pounds using the exchange rate in 2010. A unit cost of £100 per genome sequenced was used in the base case analysis [4] . The costs to screen a patient for MRSA on admission to hospital, and for a clinical sample to be taken to investigate patients with clinical features of infection (as part of an outbreak investigation), were both taken from the NHS Scotland MRSA Screening Pathfinder Programme [13] (reported in Robotham et al. [14] ). All unit costs used within the economic model were inflated to the 2017/18 price year using the most recent Pay and Prices Index within the PSSRU [15] , and are presented in Table I .
Health-related Quality of Life (HRQoL)
We applied a health-related quality of life decrement of 0.35 to patients within the symptomatic health state to generate lost quality-adjusted life years (QALYs) ( Table 1) . As MRSA carriage is asymptomatic, it was assumed that there is no QALY decrement associated with MRSA positive colonisation without infection.
Sensitivity Analysis
Sensitivity analysis was used to illustrate and assess the level of confidence associated with the conclusions of our economic evaluation. Both one-way (where input parameters are varied one by one between plausible extremes) and two-way (where more than one parameter is varied at the same time) sensitivity analyses were conducted to assess the robustness of the overall results within the model and to quantify effects of uncertainty on the cost-effectiveness of whole genome sequencing.
RESULTS
Clinical outcomes
The clinical outcomes estimated within the early model are presented in Table 2 . A cohort of 65,000 patients were ran through the model (equating to the estimated number of annual admissions for Addenbrooke's hospital between April 2012 and April 2013) [6] . Under the assumption that data from whole genome sequencing would result in a 90% reduction in MRSA acquisition, 290 new MRSA cases were avoided (which includes asymptomatic carriage and clinical infection). This gave an absolute reduction of 28.8% and an avoidance of two MRSA-related deaths.
Economic outcomes
Our base case results indicated that the use of routine, proactive MRSA sequencing would be associated with estimated cost savings of over £728,290 per annual hospitalised cohort (Table 3) . The difference in total QALYs between the two patient cohorts was more modest, with sequencing leading to an additional 14.28 QALYs gained. The results were most sensitive to changes in the probability of an MRSA negative patient acquiring MRSA during their hospital admission. The results were also sensitive to the proportion of MRSA positive patients with clinical infection at the time of presentation to hospital, and the relative reduction in cases of MRSA acquisition due to actions taken in response to whole genome sequencing data. The two-way sensitivity analysis presented in Figure 3 provides an overview of how the ICER changes when the key drivers of the cost-effectiveness results are varied simultaneously. Whole genome sequencing was estimated to be cost-effective in the majority of scenarios that have been presented. For example, sequencing was expected to be cost-effective as long as the effectiveness was over 30%, regardless of the probability that a MRSA negative patient would acquire MRSA during their hospital admission. The effectiveness could drop to 10% and sequencing is still expected to be cost-effective as long as the probability that a MRSA negative patient would acquire MRSA during their hospital admission was over 0.4%. MRSA acquisition rates were varied in sensitivity analysis and did not change the costeffectiveness conclusions of the model. We used a mortality rate of 4.6% for hospital patients who develop MRSA infection, which represents a composite death rate from all-site infections. This was derived from a recent US study [10] , and outcomes may differ in a UK setting. Furthermore, the case mix in this previous study may differ to our patient population; our patients had a very low rate of MRSA bacteraemia [16] , which is associated with high mortality [17] . Estimating the baseline QALY of an 'average' hospitalised patient was difficult because of the heterogeneity of the in-patient population as a whole, and we assumed that health-related quality of life was equal across patients upon entry to hospital. Sensitivity analysis did not indicate health related quality of life to be a key driver of the model results. It is also highly likely that we over-estimated the cost per case of MRSA infection as cost data were based on a study that assumed all patients would be treated within intensive care.
These data were used because of the lack of other viable sources from a UK setting [12] , but sensitivity analysis demonstrated that even at a minimal cost, sequencing would still be cost effective due to the costs saved through the reduction in colonised MRSA patients.
A previously published comparative effectiveness review of screening for MRSA indicated insufficient evidence to determine the effectiveness of MRSA screening strategies [18] . This did not consider the effectiveness of screening combined with sequencing. A strength of our economic analysis is that it highlights specific data collection requirements of future prospective studies that evaluate the impact and cost-effectiveness of proactive MRSA sequencing. access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis is also required.
Acknowledgement
Conflicts of interest
Sharon Peacock is a consultant to Specific Technologies and Next Gen Diagnostics. Note: As these clinical outcomes are dependent upon assumptions within the model, we would not expect them to be equal to the to the results presented in the aforementioned prospective observational cohort study [6] . Note: A negative incremental cost illustrates whole genome sequencing as cost saving. For example, a -£1,000,000 incremental cost means whole genome sequencing is £1,000,000
cheaper than current practice alone. 
